Rezdiffra (Resmetirom) Cost in Florida: Price, Insurance, and Savings in 2026

Rezdiffra is the brand name for resmetirom, an oral, once-daily thyroid hormone receptor beta (THR-β) agonist made by Madrigal Pharmaceuticals. It is not a GLP-1 receptor agonist and is not related to semaglutide or tirzepatide by mechanism, despite sometimes appearing alongside those drugs in searches. The FDA granted resmetirom accelerated approval in March 2024 for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) who have moderate-to-advanced liver fibrosis (stages F2-F3), used alongside diet and exercise.

The question that actually determines what a Florida patient pays is not "what is the list price" but which of three separate pathways applies: commercial insurance with prior authorization, a manufacturer savings card layered on top of commercial insurance, or a compounded version obtained through a licensed 503A pharmacy. Each pathway has a different cost, a different legal and evidence status, and a different failure point, and confusing them is the most common source of billing surprise.

Resmetirom (Rezdiffra) is FDA-approved only for MASH with F2-F3 fibrosis, it is not a GLP-1 drug, and its branded cash price is a manufacturer-set figure that changes over time and is not fixed by Florida law. Florida Medicaid, commercial formularies, and compounding-pharmacy pricing are all separately variable and must be checked at the time of the fill, not assumed from a national list price. Readers should verify current numbers directly with their plan, the pharmacy, or Madrigal's patient support program before assuming any dollar figure below is still current.

What resmetirom actually treats, and what it does not

Resmetirom is approved for adults with MASH and fibrosis stages F2 or F3, based on the pivotal phase 3 trial that supported its accelerated approval (published in the New England Journal of Medicine, Harrison et al., 2024). It is not approved for simple fatty liver without fibrosis, for decompensated cirrhosis (Child-Pugh B or C), or for weight loss. The accelerated approval was based on a surrogate liver-biopsy endpoint (MASH resolution and fibrosis improvement), not yet on confirmed reduction in cirrhosis or liver-related clinical events; a confirmatory outcomes trial is intended to establish that. This distinction matters for coverage decisions, because some insurers and Medicaid programs still treat accelerated-approval indications more cautiously than fully approved ones.

Reported trial results describe higher rates of MASH resolution and fibrosis improvement with resmetirom than with placebo at 52 weeks, and reported adverse effects included diarrhea and nausea more often than placebo, generally mild to moderate. Because the specific percentages in earlier versions of this article could not be independently confirmed from the primary sources available to us, editors should verify exact efficacy and safety figures against the FDA label and the original NEJM publication before republishing precise numbers.

Rezdiffra's list price and what Florida patients actually pay

Rezdiffra launched in 2024 with a manufacturer-set list price commonly reported in the low thousands of dollars per month for the standard oral regimen. Florida does not have a state-specific price cap or discount program for specialty oral hepatology drugs, so a Florida cash-pay patient's price generally tracks the national list price rather than a state-set figure. That said, the exact current dollar amount is a volatile fact: manufacturer list prices, pharmacy cash prices, and specialty pharmacy pricing can all change year to year, and this article does not have a verified, dated source confirming the 2026 figure. Confirm the current price directly with a Florida pharmacy or with Madrigal before budgeting around any specific number.

Florida Medicaid coverage

Florida Medicaid coverage decisions for specialty drugs run through the Agency for Health Care Administration's preferred drug list and each managed care organization's own prior authorization criteria. Reporting at the time of Rezdiffra's launch generally indicated that Medicaid programs, including Florida's, were slower to add MASH-specific coverage than commercial plans, and that some Medicaid coverage pathways required a concurrent type 2 diabetes diagnosis rather than a MASH diagnosis alone. This is a plan-and-year-specific formulary fact, not a fixed law, and it should be verified directly with the patient's Florida Medicaid managed care plan before assuming coverage exists or does not exist in 2026.

If a Florida Medicaid enrollee has both MASH and type 2 diabetes, prior authorization typically requires documentation of fibrosis staging (liver biopsy or a validated noninvasive test such as elastography) and confirmation that decompensated cirrhosis is not present. Denials can generally be appealed through the MCO's grievance process or a state fair hearing request; the specific steps and timelines should be confirmed with the plan.

Commercial insurance in Florida

Commercial insurers operating in Florida, including major national and regional carriers, have added Rezdiffra to formularies with prior authorization since its 2024 launch, but tier placement, step-therapy requirements, and the exact fibrosis documentation each plan accepts vary by plan and change over time. Because Rezdiffra typically sits on a specialty tier, coinsurance rather than a flat copay is common, and coinsurance on a high-cost specialty drug can still mean several hundred dollars or more out of pocket per month even with coverage, particularly before a deductible is met. The only reliable way to know an individual's cost is to call the plan's pharmacy benefits line and ask for the current tier, coinsurance percentage, and prior authorization criteria in writing.

The Madrigal savings card

Madrigal Pharmaceuticals offers a manufacturer copay savings program for commercially insured patients. Savings cards of this type generally work only for patients with commercial insurance, not Medicare, Medicaid, or other government coverage, and they typically reduce the point-of-sale copay rather than eliminate the underlying cost. The exact per-fill floor and the annual maximum benefit for 2026 are not confirmed in the sources available here and should be checked directly with Madrigal's patient support line or the savings card materials before a patient relies on a specific dollar figure.

Cost verification checklist: what is stable versus what must be re-checked

Some facts about Rezdiffra are set at the federal or clinical-trial level and change rarely. Others are set by insurers, state agencies, or individual pharmacies and can change month to month. Confusing the two categories is the most common way patients or clinicians end up with a wrong cost expectation. Use this checklist before quoting a number to a patient.

Stable facts (federal/clinical, unlikely to change quarter to quarter):

• Resmetirom's FDA-approved indication: MASH with fibrosis stage F2-F3, with diet and exercise. Verify at the FDA's drug label database.
• Resmetirom is not approved for decompensated cirrhosis or as a weight-loss drug.
• The approval is an accelerated approval based on a biopsy surrogate endpoint; confirmatory outcomes data is still pending as of this writing.
• Compounded versions of an FDA-approved drug do not carry the same bioequivalence or stability data as the branded product, regardless of state.

Volatile facts (must be re-verified at the time of the visit or fill):

• Rezdiffra's current manufacturer list price and cash price at a specific Florida pharmacy.
• Whether a specific Florida Medicaid managed care plan covers resmetirom, and under what diagnosis criteria.
• Whether a specific commercial plan (Florida Blue, Aetna, UnitedHealthcare, Cigna, or another carrier) covers resmetirom, its formulary tier, and its prior authorization requirements.
• The Madrigal savings card's current per-fill floor, annual cap, and eligibility rules.
• Whether the patient's plan uses a copay accumulator or maximizer that would prevent savings card dollars from counting toward the deductible or out-of-pocket maximum.
• Whether a specific 503A compounding pharmacy currently holds an active Florida license and what it charges for compounded resmetirom.
• Florida's telehealth prescribing rules for controlled and non-controlled specialty drugs, which can be amended by the legislature.

A simple rule: if the fact would be the same whether the patient lived in Florida or Ohio, treat it as stable and verify it once. If the fact depends on the patient's specific insurer, Medicaid plan, or pharmacy, treat it as volatile and re-verify it at every fill.

Compounded resmetirom: legal status and what it does not carry

Federally, licensed 503A pharmacies may compound a drug for an individual patient under a valid prescription. Florida's Board of Pharmacy provides state-level oversight of 503A compounding operations. This is a general statement about the 503A framework, not a citation to a specific Florida statute number, and the exact statutory citation should be confirmed by an editor before publication.

Compounded resmetirom is not FDA-approved. It has not undergone the same dissolution, stability, or bioequivalence testing as branded Rezdiffra, and a prescriber choosing this route is making an off-label, non-FDA-approved formulation decision, typically driven by cost. Reported cash prices for compounded resmetirom vary by pharmacy and are not independently confirmed here; a patient considering this option should get a written quote from a specific, currently-licensed Florida 503A pharmacy and should not assume a national average applies.

Telehealth prescribing in Florida

Florida law permits telehealth prescribing by physicians licensed in the state, and this generally extends to non-controlled specialty medications like resmetirom when the prescriber can establish an adequate diagnostic basis, such as existing labs, imaging, or noninvasive fibrosis testing (FibroScan, FIB-4, or ELF test results). This can be useful for patients in Florida counties with limited access to hepatology or gastroenterology specialists. Telehealth does not change a payer's coverage criteria: a Florida Medicaid plan that does not cover resmetirom for MASH without a diabetes diagnosis will apply the same rule whether the prescription originated in person or by telehealth.

Reducing cost: a practical sequence

1. Call the specific insurance plan's pharmacy benefits line and ask for Rezdiffra's tier placement, coinsurance percentage, prior authorization criteria, and whether a copay accumulator program applies. Ask for this in writing.
2. If commercially insured, ask the prescriber's office or a specialty pharmacy about enrolling in the Madrigal savings card before the first fill, and confirm the current benefit terms directly with Madrigal.
3. If uninsured or underinsured, ask the prescriber about manufacturer patient assistance programs and disease-specific foundations that offer copay assistance for liver disease; eligibility and fund availability change and should be confirmed directly with the organization.
4. If cost remains a barrier, discuss compounded resmetirom with the prescriber, confirm the compounding pharmacy's current Florida 503A license, and set an explicit monitoring plan (liver function tests, lipid panel, and thyroid function as clinically indicated) given the lack of bioequivalence data for compounded product.

How resmetirom compares with other MASH options on cost

Before resmetirom, no drug carried an FDA-approved MASH indication. Vitamin E and pioglitazone have been used off-label and are inexpensive by comparison, with clinical trial data (the PIVENS trial) supporting histological benefit in some patients, though without the fibrosis-specific regulatory approval resmetirom has. GLP-1 receptor agonists such as semaglutide have shown MASH-related benefit in early trials but do not carry an FDA-approved MASH indication, and their cost to a given patient depends heavily on whether the prescription can be billed under an obesity or type 2 diabetes indication rather than MASH alone. Whether resmetirom, a GLP-1, or an off-label option is cheaper for a specific patient depends almost entirely on formulary tier and savings program access rather than on the underlying list price, so a direct cost comparison should be made plan by plan rather than assumed.

What is established, what is not

Established: resmetirom's FDA-approved indication and population (MASH, F2-F3 fibrosis), its accelerated-approval status based on a biopsy surrogate endpoint, the existence of a manufacturer savings card program for commercially insured patients, the legality of 503A compounding under a valid prescription with state board oversight, and the legality of telehealth prescribing in Florida for appropriately evaluated patients.

Not established from the sources available to this article: the exact 2026 branded cash price in Florida, the exact Florida Medicaid coverage rule as currently written, exact commercial insurer coinsurance amounts, the current savings card annual cap, and exact compounded-pharmacy pricing. These require direct verification against the payer, the pharmacy, or Madrigal at the time of use, and none of them should be treated as fixed facts that apply uniformly to every Florida patient.

When to seek care rather than rely on this article

Anyone with signs of decompensated liver disease, such as jaundice, confusion, abdominal swelling, or gastrointestinal bleeding, needs urgent medical evaluation rather than a cost-shopping decision. Resmetirom is not appropriate for patients with decompensated cirrhosis, and starting or stopping any MASH treatment, including switching to a compounded formulation, should be done with the prescribing physician who can monitor liver and thyroid function.